NewsBenzingaBeam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT Benzinga 2026.10.13 11:14 (GMT+0) Open on Benzinga Other news UK's Telegraph Reported Sunday, Microsoft Pulls Plug On Deal To Lease Computing Capacity From UK Start-Up Nscale At Essex Data Centre WEA: Attractive Monthly Pay With Discount Blowing Out (NYSE:WEA) BWG: Strengthening US Dollar And Rising Bond Yields Likely To Be Headwind Trump Gave Crypto What It Wanted: Is He Also Its Biggest Problem? McDonald's: An Underrated Opportunity Hiding In Plain Sight (NYSE:MCD) How Higher Rates Create Real Estate Bargains
UK's Telegraph Reported Sunday, Microsoft Pulls Plug On Deal To Lease Computing Capacity From UK Start-Up Nscale At Essex Data Centre
